Can CEA and ctDNA predict lung cancer return?
Part of Cancer, Lungs & breathing clinical trials.
This study looks at two blood tests—CEA (a protein level) and ctDNA (tumor DNA in your blood)—to see if they can help predict whether lung cancer will come back after surgery. If you've had a malignant lung tumor removed and meet certain blood test results, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your CEA level was above 5 mg/L before surgery
- You had a blood test for tumor DNA (called MRD) before your operation
- The main tumor in your lung was completely removed during surgery
- You have had at least two follow-up blood tests for CEA and MRD within two years after surgery
- Your doctor confirmed after surgery that the tumor was a malignant (cancerous) lung tumor
- You have no other cancer in the past five years and it's not a secondary lung cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks whether a special blood test (ctDNA) taken before and after surgery can predict whether non-small cell lung cancer will come back. If it works, it may help doctors spot recurrence earlier and guide follow-up care after tumor removal.
This study checks whether a blood test that looks for leftover cancer DNA (ctDNA) after surgery can predict if your liver cancer will come back. It compares that test result with what doctors find in the removed tumor tissue.
This study tests a new way to predict if non-small cell lung cancer will return after surgery. You will give blood samples to look for cancer cells, and the team will build a model to help plan better follow-up care.
This trial is for people with early-stage liver cancer who are scheduled for surgery. It uses a simple blood test to look for tiny bits of tumor DNA after treatment, which may help predict if the cancer will come back.
This study looks at tiny particles from the body (including from lung samples) to see if they can predict whether non-small cell lung cancer comes back after surgery. It may help doctors identify people at higher risk of recurrence sooner, so follow-up plans can be better tailored.
This trial tests whether a blood test that tracks circulating tumor cells (CTCs) can help doctors detect early signs of liver cancer returning after surgery. It aims to give patients and their doctors a better way to monitor for recurrence.
Hear when a new Lung Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.